There's a big difference between RRMS and SPMS. Secondary progressive are very sick patients but spms is also a really slow, long cycle to see change and nothing has been shown to work (unlike rrms). In the context of the bio ms trial, they're enriching the population for a marker called DR2+, but it's possible if it did have a beneficial effect the study may not be long enough to prove it. The bio ms phase 2 trial in spms was very small, it actually did fail but showed the effect in the dr2+, which may have been just data dredging. Did they enrich the rrms phase 2? If no material differences despite the marker, that may be a bad sign.
Market Data 
Markets 
AI
